KBC Group
NKTR icon

KBC Group’s Nektar Therapeutics NKTR Stock Holding History

KBC Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52K Buy
+721
New +$41.1K ﹤0.01% 1634
2023
Q2 		– Sell
-1,082
Closed -$11K – 1507
2023
Q1 		$11K Hold
1,082
– – ﹤0.01% 1497
2022
Q4 		$37K Hold
1,082
– – ﹤0.01% 1451
2022
Q3 		$52K Hold
1,082
– – ﹤0.01% 1385
2022
Q2 		$62K Buy
1,082
+465
+75% +$29.3K ﹤0.01% 1380
2022
Q1 		$50K Buy
617
+46
+8% +$6.81K ﹤0.01% 1243
2021
Q4 		$116K Buy
571
+84
+17% +$18.2K ﹤0.01% 1155
2021
Q3 		$131K Sell
487
-487
-50% -$117K ﹤0.01% 1129
2021
Q2 		$250K Hold
974
– – ﹤0.01% 1145
2021
Q1 		$292K Hold
974
– – ﹤0.01% 1136
2020
Q4 		$1.37M Buy
974
+233
+31% +$60.2K ﹤0.01% 1101
2020
Q3 		$184K Sell
741
-9,500
-93% -$2.99M ﹤0.01% 1128
2020
Q2 		$3.56M Sell
10,241
-13,661
-57% -$4.26M 0.01% 581
2020
Q1 		$6.4M Sell
23,902
-7,072
-23% -$2.19M 0.05% 325
2019
Q4 		$10M Buy
30,974
+28,290
+1,054% +$8.2M 0.06% 322
2019
Q3 		$733K Buy
2,684
+1,691
+170% +$620K 0.01% 977
2019
Q2 		$530K Hold
993
– – ﹤0.01% 1051
2019
Q1 		$500K Buy
993
+198
+25% +$117K ﹤0.01% 1082
2018
Q4 		$392K Buy
795
+19
+2% +$11.5K ﹤0.01% 981
2018
Q3 		$710K Hold
776
– – 0.01% 1019
2018
Q2 		$569K Buy
+776
New +$895K ﹤0.01% 955
2018
Q1 		– Sell
-1,648
Closed -$1.48M – 1304
2017
Q4 		$1.48M Buy
+1,648
New +$975K 0.01% 669
2016
Q4 		– Sell
-3,161
Closed -$815K – 1323
2016
Q3 		$815K Buy
3,161
+1,700
+116% +$438K 0.01% 831
2016
Q2 		$312K Buy
+1,461
New +$327K ﹤0.01% 985

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

KBC Group's NKTR Position: Q1 2026 in Review

KBC Group opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 721 shares worth $52K. The stake represents ﹤0.01% of the portfolio and ranks #1634 among its holdings. This is a return to the name: KBC Group previously reported a position in NKTR as recently as Q1 2023.

KBC Group first reported a position in NKTR in Q2 2016 and has held it in 24 quarters since. The position peaked at $10M in Q4 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • KBC Group held 721 shares of Nektar Therapeutics worth $52K as of Q1 2026.
  • Nektar Therapeutics was a new KBC Group position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1634 holding.
  • KBC Group first reported a position in Nektar Therapeutics in Q2 2016 and has held it in 24 quarters since.
  • KBC Group's Nektar Therapeutics position peaked at $10M in Q4 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.